587 Background: Patient survival is impacted by several factors, one of which is stage at diagnosis. From 1976 to 2014, CRC death rate in the United States (US) declined by 51%. This retrospective study was conducted using US Surveillance, Epidemiology and End Results (SEER) data to evaluate 1- and 5-year relative survival for patients with CRC by American Joint Committee on Cancer (AJCC) stage, age and sex at diagnosis. Methods: The study included adults (age ≥20 years) in the SEER-18 registry diagnosed with CRC in 2004-2014. One- and 5-year relative survival rates were stratified by AJCC stage, age group (20-64 vs. ≥65 years) and sex. Results: One- and 5-year survival was calculated by age and stage at diagnosis (Table), and by sex (data not shown). Overall, 5-year survival rates declined compared to 1-year rates, with the biggest decline observed in stage IV patients. Survival was higher in the younger cohort than in patients ≥65 years of age regardless of stage. Both men and women diagnosed with stage IIB CRC had lower 1- and 5-year survival compared to stage IIIA and IIIB groups, consistent with previous findings. Patients with stage IV had the lowest survival irrespective of age or sex. Conclusions: Overall trends in 1- and 5-year relative survival for CRC varied by AJCC stage, age and sex. Since survival is lowest among CRC patients diagnosed at stage IV, particularly in elderly patients, it reinforces the need for early diagnosis and availability of innovative late stage therapies in this population. [Table: see text]
9004 Background: Given the importance of molecular testing and targeted therapy for mNSCLC, the MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) consortium pragmatic study assessed real-world biomarker testing rates and turnaround times (TAT) within The US Oncology Network of over 1,000 providers across the United States. Methods: This was a retrospective observational chart review study of pts with mNSCLC initiating first-line (1L) systemic therapy between 04/01/2018 and 03/31/2020. iKnowMed electronic health records were used to examine timing of biomarker testing: before 1L therapy (cohort 1), after 1L therapy (cohort 2) or no testing (cohort 3). We assessed testing rates for ALK, BRAF, EGFR, ROS1, and PD-L1; use of full next-generation sequencing panel (NGS); time from mNSCLC diagnosis (dx) to 1L therapy; TAT from biomarker orders to results; and time from mNSCLC dx to test results. Results: We identified 3474 adults. Median age was 69 years (range 23-90), 51% female, 74% with adenocarcinoma and 76% with a documented ECOG performance status of 0 or 1. Testing rates are shown in table: 90% of pts had at least one biomarker test and 46% received all 5 biomarker tests. Changes in testing rates from 2018 to 2020 were 51% to 59% for BRAF, 71% to 71% for EGFR, 71% to 70% for ALK, 69% to 67% for ROS1, 82% to 84% for PD-L1, and 42% to 49% for pts tested for all 5 biomarkers. NGS testing increased from 33% to 44% (p<0.0001). The median (interquartile range [IQR]) time from mNSCLC dx to 1L therapy for all pts was 35 (22, 55) days. Median (IQR) TAT from biomarker testing orders to results ranged from 10 (6, 17) to 15 (10, 22) days for the individual biomarkers; and time from mNSCLC dx to biomarker results ranged from 14 (7, 26) to 21 (12, 36) days by biomarker. Conclusions: This real-world study showed that most pts received at least one biomarker test prior to 1L, but <50% received all 5 tests. NGS testing occurred in <50% of pts but increased over the periods examined. Median time from dx to 1L therapy was about 5 weeks and TAT from orders to results about 2 weeks. Analyses by histology and other trends will be reported. These data will be compared to the next phase of the MYLUNG study, which will evaluate contemporary ordering practices and TATs prospectively[Table: see text]
surement with more than one endpoint is the generation of a cardinal index/score. Without the prioritization and weighting of multiple endpoints a deduction of recommendations might be questionable. METHODS: A pilot study was conducted to elicit patients' preferences about antiviral therapy of chronic hepatitis C. For the Discrete-Choice-Experiment (DCE), 7 attributes were selected with 3 Levels each. Therefore an orthogonal, balanced and efficient design was used and results were analysed with random effects logit models. RESULTS: Patients and experts prioritized the respective endpoints in almost the same order, but weighted them differently. Sustained-Virological-Response received the highest weight followed by frequency of application (patients) or duration of therapy (experts). CONCLUSIONS: Aim was to demonstrate how DCEs can be used to empirically determine which PREs should be included in the efficiency frontier analysis. Further it is demonstrated how such methods can be used to prioritize across such multiple efficiency frontiers. The survey demonstrated how DCEs could be used to empirically determine which PREs are important in antiviral treatment of chronic hepatitis C. The results could be used for the development of innovative therapeutic schemes and new drugs which could meet patients' needs. For IQWiG purposes the weights of PREs are included in the health economic evaluation. OBJECTIVES:To determine health care provider perceptions about timing of 'rapid' warfarin reversal-related patient care events using novel survey methodology. METHODS: Forty-eight adult and pediatric trauma centers were contacted to participate in a direct-to-provider (DTP) survey. Participants were asked to provide aggregate information about patients receiving fresh-frozen plasma (FFP) for acute warfarin reversal. RESULTS: Nineteen to 25 health care professionals from 18 centers provided information by survey. Average perceptions of time needed to infuse FFP under this setting (mean 4.6 hrs from time of triage; 95% CI 1.0 -8.2 hrs) are consistent with actual, published values. In contrast, average perceptions of time needed for initial International Normalized Ratio (INR) normalization using FFP (mean 5.8 hrs; 95% CI 2.8 -8.8 hrs) underestimate actual, published values by 6 -26 hrs. Health care providers perceived that relatively little cumulative time lapses (1.6 hrs, on the average) for completing the first FFP infusion. There is little perceived time lag between ordering and beginning the first FFP infusion (0.3 hrs, on the average), consistent with actual, published values. There is substantial reported time (an additional 3.0 hrs, on the average) needed to complete subsequent FFP infusions, amounting to 52% of all perceived time lapsing for initial INR normalization in this setting. CONCLUSIONS: DTP survey methodology appears to be an efficient method for gathering clinical information for research purposes. Healthcare providers may have perceptions that are different from published studies, including inaccurate percep...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.